Clinical Education InitiativeMenu
Search
Home > Courses > HIV and Aging

HIV and Aging

HIV and Aging
HIV and Aging
Play
Sorry, this learning module is not available for mobile devices.
Resource ID: CM385
Original Presentation: 5/12/2015
Web Posting: 8/19/2015
CE Expiration: 05/12/2018
Presenter
  • Peter Hunt, MD
    Associate Professor of Medicine
    HIV/AIDS Division University of California, San Francisco, CA
Learning Objectives
At the completion of this educational session, participants will:
  1. Know that HIV increases the risk of several, but not all, age-associated morbidities.
  2. Be aware that immune activation persists despite suppressive ART and predicts many of these morbidities.
  3. Understand that some immunologic mechanisms that drive morbidity/mortality in treated-HIV-infection may be distinct from those in aging.
  4. Appreciate the interventional targets that are being pursued in interventional trials to reduce morbidity and mortality during ART-mediated viral suppression.
Presenter Bio
Peter Hunt, MD
Peter Hunt is an Associate Professor of Medicine in the HIV/AIDS division at the University of California San Francisco and Vice Chair of the AIDS Clinical Trials Group’s Inflammation and End Organ Disease Transformative Science Group. His primary research focus is on the inflammatory consequences of HIV infection. His clinic-based translational research program seeks to understand both the causes and consequences of persistent immune activation both in the presence and the absence of antiretroviral therapy. He collaborates extensively with a multi-disciplinary team of investigators to assess the impact of persistent immune activation on mortality and chronic diseases associated with aging, as well as on the persistence of HIV in cellular reservoirs. He also conducts pilot clinical trials of novel immune-based interventions designed to decrease immune activation. Dr. Hunt also leads a translational research program in Mbarara, Uganda, focused on the determinants of immune recovery during suppressive antiretroviral therapy in that setting and has helped develop a large mucosal immunology program at San Francisco General Hospital focused on the impact of HIV on gut-associated lymphoid tissue and the determinants of microbial translocation in HIV infection.
Continuing Education Credit

This CME activity was approved for AMA PRA Category 1 Credit™ on May 12, 2015 and will terminate May, 2018.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length. 

  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz. 
  • You must achieve at least 70% correct to receive your CME certificate. 
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity. 

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement 

Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.  

  • Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose. 
  • Dr. Hunt (Presenter) had the following personal financial relationships in the previous 12 months with manufacturers of the products and/or services that may be presented in this CME activity: Consultant to Merck, Gilead, and Tobira; honoraria recipient from Gilead, and Janssen. Dr. Hunt submitted his slides in advance for adequate peer review, and will support his presentation and clinical recommendations with the best available evidence from the medical literature.

Financial Support

This meeting of the Physicians’ Research Network (PRN) and enduring material were funded in part by educational grants from: Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co, and ViiV Healthcare.

PRN Learning Modules